SANTHERA N news, videos and press releases - Page 2
For more news please use our advanced search feature.
SANTHERA N - More news...
SANTHERA N - More news...
- Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
- Santhera Updates on Ongoing NDA Submission for Vamorolone
- Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
- Santhera Announces Corporate Calendar Update
- Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
- Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
- Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
- Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study
- Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress
- ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamorolone in Becker Muscular Dystrophy
- Santhera Completes Subsequent Capital Increase for Financing Arrangements
- Santhera and ReveraGen to Present Phase 2a/2b Efficacy and New Safety Data with Vamorolone at Forthcoming Conferences
- Santhera Completes Capital Increase for Financing Arrangements
- Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 2021 Financial Results
- Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy
- Santhera Completes Capital Increase for Financing Arrangements
- Santhera Completes Capital Increases for Financing Arrangements
- Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
- Santhera Reports End Results on Convertible Bond Exchange Offer
- Santhera Reports Interim Results on Convertible Bond Exchange Offer
- Santhera Commences Convertible Bond Exchange Offer and Continues to Seek Votes on the Bondholders' Resolution
- Santhera Launches Exchange Offer for its CHF 60 Million Convertible Bonds
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial
- Santhera Implements Reorganization and Secures Financing to Advance Vamorolone to Pivotal Read-out in Duchenne Muscular Dystrophy
- Santhera Completes Capital Increase for Financing Arrangements
- Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone
- Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
- Santhera Announces Full Enrollment of ReveraGen’s Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy
- Santhera Closes First Tranche of Financing Transaction
- Santhera Completes Capital Increase for Financing Arrangements
